Brigimadlin
- Generic Name
- Brigimadlin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C31H25Cl2FN4O3
- CAS Number
- 2095116-40-6
- Unique Ingredient Identifier
- 9A934ZAN94
- Associated Conditions
- -
- Associated Therapies
- -
Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Phase 2
Active, not recruiting
- Conditions
- Liposarcoma, Dedifferentiated
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 401
- Registration Number
- NCT05218499
- Locations
- 🇩🇪
Technische Universität Dresden, Dresden, Germany
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath